Advertisement
Screener

NIAGEN BIOSCIENCE, INC. (NAGE) Overview

NIAGEN BIOSCIENCE, INC. (NAGE) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.01; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.07; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.05; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.04; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.80$3.64$4.73$6.15$8.00$10.402025-09-292026-09-29$1.13$1.90$3.19$5.36$9.01$15.132021-09-292026-09-29$1.13$2.00$3.54$6.28$11.11$19.682016-09-292026-09-29$0.43$0.92$1.98$4.25$9.15$19.682008-06-252026-09-29$0.43$0.92$1.98$4.25$9.15$19.682008-06-252026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$2.95
Previous close
$2.98
Change
-$0.03
Change (%)
-1.01%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

NAGE
-53.46%
S&P 500
(m)

1 year

NAGE
-70.10%
S&P 500
(m)

3 years

NAGE
+102.72%
S&P 500
(m)

5 years

NAGE
-51.08%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.01

-0.070.010.090.170.2531 Mar 2025: estimate (m); actual 0.0631 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.0430 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.0530 Sept 2025(m)31 Mar 2026: estimate (m); actual 0.0731 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.0130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.01(m)(m)
1 Jan 202631 Mar 2026(m)0.07(m)(m)
1 Jul 202530 Sept 2025(m)0.05(m)(m)
1 Apr 202530 Jun 2025(m)0.04(m)(m)
1 Jan 202531 Mar 2025(m)0.06(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.20

-0.48-0.27-0.050.160.3831 Dec 2021: estimate (m); actual -0.4031 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.2431 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.0731 Dec 2023(m)31 Dec 2024: estimate (m); actual 0.1131 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.2031 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.20(m)(m)
1 Jan 202431 Dec 2024(m)0.11(m)(m)
1 Jan 202331 Dec 2023(m)-0.07(m)(m)
1 Jan 202231 Dec 2022(m)-0.24(m)(m)
1 Jan 202131 Dec 2021(m)-0.40(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 29.79M ■ Earnings 0.96M — Profit margin 3.23%

-4.08M2.2%9.97M8.5%24.02M14.8%38.06M21.1%30 Sept 2025: revenue 33.99M; earnings 4.58M; profit margin 13.47%30 Sept 202531 Dec 2025: revenue 33.84M*; earnings 4.13M*; profit margin 12.21%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 31.47M; earnings 6.32M; profit margin 20.07%31 Mar 202630 Jun 2026: revenue 29.79M; earnings 0.96M; profit margin 3.23%30 Jun 2026

31 Dec 2025 ■ Revenue 129.42M ■ Earnings 17.38M — Profit margin 13.43%

-34.06M-24.0%26.28M-11.2%86.61M1.6%146.94M14.4%31 Dec 2022: revenue 72.05M; earnings -16.54M; profit margin -22.96%31 Dec 202231 Dec 2023: revenue 83.57M; earnings -4.94M; profit margin -5.91%31 Dec 202331 Dec 2024: revenue 99.60M; earnings 8.55M; profit margin 8.58%31 Dec 202431 Dec 2025: revenue 129.42M; earnings 17.38M; profit margin 13.43%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$2.95(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$2.95High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning NAGE

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
379.71K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-4.83%*
Total return · month
-10.58%*
Total return · quarter
-10.31%*
Total return · half year
-29.53%*
Total return · year to date
-53.46%*
Total return · 1 year
-70.10%*
Total return · 3 years
102.72%*
Total return · 5 years
-51.08%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

NIAGEN BIOSCIENCE, INC. Overview

View more →

(m)

(m)

SEC CIK
1386570
Industry (SIC)
2833 Medicinal Chemicals & Botanical Products
Country of operation
United States
Business address
10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, California, 90024, United States
Fiscal year end
1231
Phone
310-388-6706

Similar stocks

Stock NameCountryMarket CapPE Ratio
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
Canopy Growth Corp (CGC)$0.395B
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Cronos Group Inc. (CRON)$1.223B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87